MC-Val-Cit-PAB-tubulysin5a |
| Catalog No.GC36575 |
MC-Val-Cit-PAB-tubulysin5a est un conjugué médicament-lieur pour l'ADC avec une puissante activité antitumorale en utilisant la tubulysine M (un inhibiteur de la tubuline), lié via le lieur ADC MC-VC(S)-PABQ. MC-Val-Cit-PAB-tubulysin5a est efficace contre les lignées cellulaires de lymphomes multirésistants et les tumeurs.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 2055896-86-9
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
MC-Val-Cit-PAB-tubulysin5a has a bioreversible linkage based on a quaternary ammonium for targeted delivery and it can improve pharmacokinetics and the therapeutic index. MC-Val-Cit-PAB-tubulysin5a is used for the antibody-drug conjugates (ADC) that are effective and stable in vitro and in vivo to treat various diseases or disorders[1].
[1]. Staben LR, et al. Targeted drug delivery through the traceless release of tertiary and heteroaryl amines from antibody-drug conjugates. Nat Chem. 2016 Dec;8(12):1112-1119.
Average Rating: 5 (Based on Reviews and 17 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *